Skip to main content
. Author manuscript; available in PMC: 2015 Mar 24.
Published in final edited form as: Neuropharmacology. 2014 Mar 16;82:41–48. doi: 10.1016/j.neuropharm.2014.03.004

Fig. 3.

Fig. 3

Effects of PF administered following KYN (Experiments 2 and 4). a Compared with the amplitudes of glutamatergic transients evoked by nicotine in animals treated with vehicle, systemic KYN administration significantly attenuated amplitudes (see Results for ANOVAs). Post hoc comparisons indicated significant attenuation of the amplitudes of glutamatergic transients for all time points except for the last time point (270 min) when amplitudes in vehicle-treated rats declined and thereby limited the demonstration of an additional dampening by KYN. Administration of the KAT II inhibitor PF after KYN was ineffective. b Representative traces depicting the effect of KYN and PF on nicotine-evoked glutamatergic transients recorded at t = 90 min.